Embolic Protection Devices during percutaneous cardiac procedures (PCI and TAVI)

Series
Cardiovascular
Status
Published
Date
Number of report
060

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for use of Embolic Protection Devices during percutaneous cardiac procedures. 


The following clinical situations are considered: 

  • Use of Embolic Protection Device during percutaneous transluminal coronary angioplasty with insertion of single bare metal stent
  • Use of Embolic Protection Device during percutaneous transluminal transcatheter aortic valve replacement

The only reimbursement within public / statutory health insurance systems is considered.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of Embolic Protection Devices for percutaneous cardiac procedures (PCI and TAVI):

  • Allium Medical (WIRION EPD)
  • Boston Scientific (FilterWire EZ)
  • Claret Medical (Sentinel)
  • Contego Medical
  • Cordis (ANGIOGUARD)
  • Innovative Cardiovascular Solutions (Emblock)
  • Keystone Heart Ltd (TriGuard)
  • Transverse Medical (POINT-GUARD)

Table of content is not available at the moment. Report is still ongoing.

21

Sep 2021

In August 2021, the mini-HTA evaluation of the robot-assisted percutaneous coronary intervention was released. The method was described as safe and effective. After the introduction into the clinical practice, the method should be followed up for two years with a sufficient number of procedures to understand the real benefit. All procedures are to be registered in the Norwegian Registry for Invasive Cardiology.

Read more

06

Jul 2021

In June 2021, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (laser lithotripsy for difficult-to-treat bile duct stones and percutaneous insertion of a closure device to repair a paravalvular leak around a replaced mitral or aortic valve), one new Medical Technologies Guidance (Plus Sutures for preventing surgical site infection), and four new Medtech Innovation Briefings (RapidAI for analyzing CT/MRI brain scans, WoundExpress, Magtrace and Sentimag, and SYNE-COV). Also, four clinical guidelines were updated, and two new published.

Read more

28

Jun 2021

In mid-June 2021, the document "Changes and innovations in the 2022 LKF model" (Änderungen und Neuerungen in den LKF-Modellen 2022) was published. The document summarizes the most significant changes and innovations in the LKF model for inpatient and outpatient care. The newly added procedure codes concern mainly the cardiovascular, e-Health, and gastrointestinal area.

Read more

09

Jun 2021

For the first time in three years, the Institute for Quality and Efficiency in Health Care (IQWiG) received data within the framework of the early benefit assessment of new examination and treatment methods (NUB) with high-risk medical devices according to §137h of Social Code Book (SGB) V. This involves seven invasive therapeutic cardiovascular, pulmonary, neurological, gastrointestinal, and urological procedures.

Read more

26

May 2021

On May 6, 2021, the Federal Joint Committee (G-BA) announced the start of consultations about the design of three co-funded studies for cardiovascular methods in accordance with §137e SGB V.

Read more
(we accept only company emails)